Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-09-09
2008-09-09
Robinson, Hope A (Department: 1652)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S012200, C435S007100
Reexamination Certificate
active
10271869
ABSTRACT:
The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
REFERENCES:
patent: 3721252 (1973-03-01), Ayella
patent: 4411890 (1983-10-01), Momany
patent: 4511503 (1985-04-01), Olson et al.
patent: 4876242 (1989-10-01), Applebaum et al.
patent: 4988675 (1991-01-01), Froesch et al.
patent: 5068224 (1991-11-01), Fryklund et al.
patent: 5077276 (1991-12-01), Ballard et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5106832 (1992-04-01), Froesch et al.
patent: 5126324 (1992-06-01), Clark et al.
patent: 5164370 (1992-11-01), Ballard et al.
patent: 5187151 (1993-02-01), Clark et al.
patent: 5202119 (1993-04-01), Clark et al.
patent: 5206235 (1993-04-01), Fisher et al.
patent: 5210017 (1993-05-01), Carlsson et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5273961 (1993-12-01), Clark
patent: 5342763 (1994-08-01), Swartz
patent: 5374620 (1994-12-01), Clark et al.
patent: 5444047 (1995-08-01), DiPasquale
patent: 5466670 (1995-11-01), Dunger et al.
patent: 5470828 (1995-11-01), Ballard et al.
patent: 5514646 (1996-05-01), Chance et al.
patent: 5534617 (1996-07-01), Cunningham et al.
patent: 5565428 (1996-10-01), Clark et al.
patent: 5569648 (1996-10-01), Lewis et al.
patent: 5593844 (1997-01-01), Carlsson et al.
patent: 5597797 (1997-01-01), Clark
patent: 5622932 (1997-04-01), DiMarchi et al.
patent: 5652214 (1997-07-01), Lewis et al.
patent: 5703045 (1997-12-01), Lewis et al.
patent: 5714460 (1998-02-01), Gluckman et al.
patent: 5741776 (1998-04-01), Clark et al.
patent: 5750373 (1998-05-01), Garrard et al.
patent: 5776897 (1998-07-01), Lewis et al.
patent: 5821047 (1998-10-01), Garrard et al.
patent: 5834250 (1998-11-01), Wells et al.
patent: 5843899 (1998-12-01), Halloran
patent: 5891722 (1999-04-01), Fuks et al.
patent: 5985830 (1999-11-01), Acott et al.
patent: 5994303 (1999-11-01), Arrhenius-Nyberg et al.
patent: 128733 (1984-12-01), None
patent: 135094 (1985-03-01), None
patent: 214826 (1987-03-01), None
patent: 230869 (1987-08-01), None
patent: 288451 (1988-10-01), None
patent: 294021 (1988-12-01), None
patent: 369943 (1990-05-01), None
patent: 375438 (1990-06-01), None
patent: 379338 (1990-07-01), None
patent: 560723 (1993-09-01), None
patent: 434652 (1994-11-01), None
patent: 436469 (1995-02-01), None
patent: 434625 (1995-04-01), None
patent: 681842 (1995-11-01), None
patent: 742228 (1996-11-01), None
patent: 965596 (1999-12-01), None
patent: WO 89/05822 (1989-06-01), None
patent: WO 89/08667 (1989-09-01), None
patent: WO 89/09268 (1989-10-01), None
patent: WO 89/09792 (1989-10-01), None
patent: WO 91/03253 (1991-03-01), None
patent: WO 91/19510 (1991-12-01), None
patent: WO 92/11865 (1992-07-01), None
patent: WO 92/13565 (1992-08-01), None
patent: WO 92/15679 (1992-09-01), None
patent: WO 93/08826 (1993-05-01), None
patent: WO 93/20836 (1993-10-01), None
patent: WO 93/23071 (1993-11-01), None
patent: WO 93/25219 (1993-12-01), None
patent: WO 94/04569 (1994-03-01), None
patent: WO 94/16722 (1994-08-01), None
patent: WO 94/16723 (1994-08-01), None
patent: WO 95/07697 (1995-03-01), None
patent: WO 95/17422 (1995-06-01), None
patent: WO 95/17423 (1995-06-01), None
patent: WO 96/01124 (1996-01-01), None
patent: WO 96/15148 (1996-05-01), None
patent: WO 96/33216 (1996-10-01), None
patent: WO 96/37514 (1996-11-01), None
patent: WO 96/40189 (1996-12-01), None
patent: WO 96/40750 (1996-12-01), None
patent: WO 97/37010 (1997-10-01), None
patent: WO 97/39032 (1997-10-01), None
patent: WO 98/20036 (1998-05-01), None
patent: WO 98/45427 (1998-10-01), None
patent: WO 98/56406 (1998-12-01), None
patent: WO 99/32620 (1999-07-01), None
patent: 99/51262 (1999-10-01), None
patent: WO 00/20023 (2000-04-01), None
patent: WO 00/23469 (2000-04-01), None
patent: WO 00/40612 (2000-07-01), None
patent: WO 00/69901 (2000-11-01), None
patent: WO 01/72771 (2001-10-01), None
Magee BA, Shooter GK, Wallace JC, Francis GL. Insulin-like growth factor I and its binding proteins: a study of the binding interface using B-domain analogues.Biochemistry. 1999 Nov. 30;38(48):15863-70.
Wells, Biochemistry, vol. 29, pp. 8509-8517, 1990.
Alberts et al.Molecular Biology of the Cell, 3RD edition, New York:Garland Publishing, Inc. pp. 119 (1994).
Amin and Abramson., “The Role of Nitric Oxide in Articular Cartilage Breakdown in Osteoarthritis.”Curr. Opin. Rheum. 10(3):263-268 (1998).
Arend W. P. et al., “Interleukin-1 Receptor Antagonist: Role in Biology”Ann. Rev. Immunol. 16:27-55 (1998).
Bach and Rechler., “Insulin-Like Growth Factor Binding Proteins.”Diabetes Reviews. 3(1):38-61 (1995).
Bagley et al., “A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide”Biochemical Journal259 (3):665-671 (May 1, 1989).
Ballard et al., “Does IGF-I Ever Act Through the Insulin Receptor?”The Insulin-Like Growth Factors and Their Regulatory Proteins., Baxter, eds., Amsterdam: Elsevier pp. 131-138 (1994).
Bar et al., “Tissue Localization of Perfused Endothelial Cell IGF Binding Protein is Markedly Altered by Association with IGF-I.”Endocrinology. 127 (6):3243-3245 (1990).
Baragi et al., “Transplantation of Adenovirally Transduced Allogeneic Chondrocytes into Articular Cartilage Defects In Vivo.”Osteoarthritis and Cartilage. S(4):275-282 (1997).
Baragi et al., “Transplantation of Transduced Chondrocytes Protects Articular Cartilage from Interleukin 1-Induced Extracellular Matrix Degradation”J. Clin. Invest. 96(5):2454-2460 (Nov. 1995).
Barinaga, M., “Neurotrophic Factors Enter the Clinic [News].”Science. 264:772-774 (1994).
Barnett and Owens, “Insulin analogues”Lancet349(9044):47-51 (Jan. 4, 1997).
Baron et al., “Dexamethasone acts locally to inhibit longitudinal bone growth in rabbits”American Journal of Physiology263 (3 Pt 1) :E489-E492 (Sep. 1992).
Barreca et al., “Short stature associated with high circulating insulin-like growth factor (IGF) -binding protein-1 and low circulating IGF-II: effect of growth hormone therapy”Journal of Clinical Endocrinology&Metabolism83(10):3534-3541 (Oct. 1998).
Bass et al., “Hormone Phage: An Enrichment Method for Variant Proteins with Altered Binding Properties”Proteins: Structure, Function, and Genetics8(4):309-314 (1990).
Batch et al., “Abnormal regulation of insulin-like growth factor binding proteins in adolescents with insulin-dependent diabetes”Journal of Clinical Endocrinology&Metabolism73(5):964-968 (Nov. 1991).
Baxter & Martin, “Binding Proteins for Insulin-Like Growth Factors in Adult Rat Serum. Comparison With Other Human and Rat Binding Proteins”Biochem.&Biophys. Res. Comm. 147(1):408-415 (1987).
Baxter et al., “High Molecular Weight Insulin-like Growth Factor Binding Protein Complex”Journal of Biological Chemistry264(20):11843-11848 (1989).
Baxter et al., “Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily”Endocrinology139(10):4036 (Oct. 1998).
Baxter et al., “Structural determinants for binary and ternary complex formation between insulin-like growth factor-I (IGF-I) and IGF binding protein-3”Journal of Biological Chemistry267(1):60-65 (Jan. 5, 1992).
Baxter, “Physiological Roles of IGF Binding Proteins”Modern Concepts of Insulin-like Growth Factors, Spencer, eds., Elsevier, New York pp. 371-380 (1991).
Baxter, R., “The Insulin-Like Growth Factors and Their Binding Proteins”Comp. Biochem. Physiol. 91B(2):229-235 (1988).
Baxter., “The Somatomedins: Insulin-Like Growth Factors.”Advances in Clinical Chemistry. 25:49-115 (1986).
Bayne et al., “
Chen Yvonne Man-Yee
Clark Ross G.
Cochran Andrea G.
Dubaquie Yves
Fielder Paul J.
Dreger, Esq. Ginger R.
Genentech Inc.
Goodwin & Procter LLP
Kresnak Mark T.
Robinson Hope A
LandOfFree
Method for treating cartilage disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating cartilage disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating cartilage disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3916008